Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome
Singhal S, Riggs E, Ruth K, Chavez-Salas J, Chertock Y, Daly M, Hall M. Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome. JCO Precision Oncology 2024, 8: e2400562. PMID: 39546469, PMCID: PMC11573245, DOI: 10.1200/po-24-00562.Peer-Reviewed Original ResearchConceptsLynch syndromeLifetime risk of colorectal cancerColorectal cancerRisk of colorectal cancerCancer prevention optionsFactors associated with useNonsteroidal anti-inflammatory drugsDisease-related factorsChemoprevention uptakeScreening behaviorAspirin chemopreventionRelative risk reductionResearch invitationsPatients' perceptionsLifetime riskAdvocacy websitesASA/NSAID useElectronic surveyFox Chase Cancer CenterPrevention optionsCancer CenterRisk reductionMultivariate modelChemopreventive benefitsParticipantsPerceptions of cancer prevention options for Lynch syndrome (LS) in a multi-national convenience sample.
Hall M, Singhal S, Osorio N, Chavez J, Riggs E, Chertock Y, Daly M. Perceptions of cancer prevention options for Lynch syndrome (LS) in a multi-national convenience sample. Journal Of Clinical Oncology 2024, 42: 77-77. DOI: 10.1200/jco.2024.42.3_suppl.77.Peer-Reviewed Original ResearchLynch syndromeCancer prevention optionsCA riskNon-usersOne-time surveySupport groupsConvenience sampleCA preventionStratified analysisFox Chase Cancer CenterNegative public attitudesPrevention optionsColonoscopyMSI-H tumorsCA-PTPerceptions of efficacyCancer CenterSide-effect riskPersonal historyBelief statementsSide effect concernsInternational patientsSide effectsMSI-HRisk